JDR_cmyk‘Join dementia research’ is the brand new, online service that can connect volunteers and researchers, working together on vital studies into dementia.

New studies are being added to the service all the time, and we’re pleased to be able to inform you about the TOMMORROW study, that has just begun recruiting!


Study Background

The World Health Organisation (WHO) has reported that there are over 35.6 million people living with dementia worldwide. This figure is expected to double by 2030.

At the moment, there is no cure for dementia. It is very important for us to try to find out how we can slow down or delay the inevitable onset of memory problems due to Alzheimer’s Disease, in identified high risk individuals.

Study Goals

The TOMMORROW trial is a clinical research study that is designed to pursue two objectives:

tomorrowThe first goal is to see if it is possible to predict if a person will develop Mild Cognitive Impairment (MCI), subtle changes in a person’s memory and thinking abilities, based on his/her genes.

This would involve taking a blood sample from the participant’s arm to examine two genes named APOE and TOMM40.
TOMM40 is detected by a new investigational test and is being studied to determine if it can help identify if a person is at increased risk of developing MCI due to AD.
The results of these genetic tests will not be provided to you nor will they be shared with the public.

The second goal of this study is to test an investigational medication, pioglitazone, to see if it can delay the emergence of MCI due to AD in people who are currently cognitively normal but thought to be at high risk for developing MCI due to AD based on the results of the investigational test.

This is not a prevention study, but is intended to assess for the potential to delay the onset of MCI due to AD.
This is a double blind, randomized, placebo controlled study which means that some people enrolled will receive the active medication and some people will receive a pill containing no medication, known as a placebo.
Neither you nor any member of the study team will know which group you will be assigned to. This study medication is taken orally on a daily basis.


patient-carer-BDR-image1Eligibility

This study is seeking individuals between the ages of 65 and 83 that do not have a diagnosis of Alzheimer’s disease or memory problems, are in generally good physical and mental health, and do not have a current diagnosis of mental illness.

You are also required to have a project partner, such as a spouse, companion, close friend or adult family member.
This person will provide information about your thinking abilities and behaviour throughout the study and will need to participate in regular study visits.
Other study requirements will be reviewed by site study staff.

To see if you match the requirements, sign up to ‘Join dementia research’ today – you may find other studies that are also recruiting for people just like you!

For more information, you can visit the website for The Tommorrow Study as well.


Have you taken part in a study?

We are really interested in hearing from people taking part in studies on ‘Join dementia research’. What would they say to others considering signing up with ‘Join dementia research’?

Please let us know if you, or someone you know, would be interested in sharing their story. Get in touch with us at comms.jdr@nihr.ac.uk.

You can follow us on Facebook and Twitter!